16 results about "Lymphatic vessel" patented technology

The invention patent is titled "Dragon and Cypress Gel," belonging to the pharmaceutical category. The main components of Dragon and Cypress Gel are: Phellodendron bark, earthworm, dragon's blood, Oldenlandia diffusa, Sophora flavescens, and Bletilla striata. In recent years, research on cervicitis and cervical lesions has shown good results using external treatments of traditional Chinese medicine. Vaginal cervical medications are characterized by high local drug concentration, low dosage, and safety and effectiveness, receiving high clinical evaluation. The vagina and cervix have abundant capillaries and lymphatic vessels, and lack clearly defined nerve endings, resulting in minimal pain stimulation for patients during administration. This makes it an effective drug release site for specific diseases such as cervicitis and vaginitis. Traditional Chinese medicine gels are a novel type of external preparation of traditional Chinese medicine. They are made by dissolving or uniformly dispersing traditional Chinese medicine in a gel. These gels adhere tightly to the treatment site for a relatively long time, exhibiting good bioadhesion, and are simple to prepare. It is suitable for use on skin, mucous membranes and cavities. It not only avoids the first-pass effect of enzymes and acids in the gastrointestinal tract that exists in oral administration, but also reduces the adverse reactions of drugs. It has the characteristics of good spreadability, non-greasy feeling, easy to wash off, good transdermal absorption, and comfortable use.

Organ-on-chip system, including a bio-engineered lung region that is functionally connected to a bio-engineered lymphatic region via a functionalized connection region. The bio-engineered lung region includes cultured or transplanted lung cells / tissue, which can mimic in vivo lung function, and the bio-engineered lymphatic region includes lymphatic cells / tissue, which can mimic in vivo lymphatic function. The connection region allows for stimuli and cell secretions to be transported between the lung region and the lymphatic region to confer immune competency to the lung region, as the lymphatic region can generate an immune response based on stimuli received from the lung region, for example, in response to infections or therapeutic agents

The application belongs to the technical field of biological medicine, and provides an application of H151 in preparation of a medicine for treating lymphatic vessel dysfunction, wherein the application uses the STING protein antagonist H151 to treat the lymphatic vessel dysfunction, shows that H151 can significantly inhibit the activation of the cGAS-STING signal path, and then inhibit the secretion of inflammatory factors in the lymphatic endothelial cell, and effectively improve the function of the lymphatic endothelial cell. Therefore, the application uses the STING protein antagonist H151 to treat the lymphatic vessel dysfunction related diseases, opens a new way and method, and effectively solves the problem that the lymphatic vessel dysfunction lacks effective treatment means at present.

The present disclosure relates to systems, devices, and methods for subcutaneously cutting and treating tissue and cellulite with non-invasive acoustic waves. Embodiments of the present disclosure refer to systems, devices, and methods that use unfocused or planar, non-cavitating acoustic waves to induce physical effects in tissue such as dermis, fat, muscle, bone, blood vessels, liver tissue, etc. The physical effects include disruption of the fibrous extracellular matrix of the target tissue. Embodiments of the present disclosure include the application of multiple rapid acoustic pulses (e.g., shockwaves) to cause the breakdown of the fibrous extracellular matrix to reduce the appearance of cellulite or scarring in the treated area. Such unfocused or planar, non-cavitating acoustic waves can induce tissue responses such as reduced fibrosis, induction of angiogenesis or lymphangiogenesis, etc.

The application belongs to the technical field of biomedical diagnosis, and provides application of neutrophil extracellular traps in preparation of a lymphangitic inflammation diagnosis kit, wherein the application first discloses high expression of neutrophil extracellular traps in lymphangitic inflammation lesion tissues, and confirms that the expression level is closely related to disease occurrence and development, so that the neutrophil extracellular traps are used as an early diagnosis index to fill the technical blank of lack of early non-invasive screening means for lymphangitic inflammation in the prior art, precise diagnosis and disease monitoring of subclinical stage occult lymphangitic inflammation can be realized, misdiagnosis and missed diagnosis can be effectively avoided, reliable technical support and theoretical basis are provided for early prevention and timely intervention of serious complications such as secondary lymphedema, and thus the incidence of complications is significantly reduced and the prognosis of patients is improved.

This invention discloses an instrument for connecting lymphatic vessels and blood vessels, comprising a vascular connecting tube, a connecting lumbar tube, and at least one connecting branch tube. The connecting branch tube includes interconnected primary and secondary branches, through which lymph fluid can enter the bloodstream. This instrument enables a stable connection between lymphatic vessels and blood vessels via the instrument itself, rather than relying solely on surgical sutures. This simplifies the surgical procedure, reduces the stringent requirements on the surgeon's skills, significantly reduces the difficulty and risk of the surgery, decreases the incidence of postoperative complications, improves patient recovery speed and treatment effectiveness, and provides a more convenient and reliable connection method, greatly enhancing the convenience, safety, and effectiveness of connecting lymphatic vessels and blood vessels.

This invention relates to the field of biomedical technology and provides the application of taquimod in the preparation of drugs for regulating lymphatic inflammatory responses. Through bioinformatics analysis and cell experiments, this invention demonstrates that taquimod can specifically inhibit the abnormally activated S100A9 / RAGE signaling pathway in lymphatic inflammation, significantly reduce the expression of inflammatory factors, and effectively restore the proliferation, migration, and tube formation function of lymphatic endothelial cells. This provides a novel drug treatment approach based on molecular mechanisms for treating diseases related to lymphatic inflammatory responses such as lymphedema. Furthermore, taquimod, as an oral formulation with proven safety in clinical trials, exhibits good patient compliance and is suitable for long-term use. Compared to existing symptomatic treatments, it holds promise for fundamentally interrupting the vicious cycle of inflammation that drives disease progression, and thus has significant clinical application potential.

The application discloses peripheral blood CD8 + The application discloses an application of T cell absolute count as a biomarker in prevention or evaluation of pulmonary lymphangioleiomyomatosis. The application breaks the limitation of traditional methods mainly depending on imaging or single serological index, provides a novel diagnosis strategy based on peripheral blood immune cell absolute count, is convenient for sampling (venous blood can be drawn), has low detection cost, can be used for dynamic monitoring of patient's disease severity and prognosis stratification, and lays a solid foundation for subsequent development of immune regulation target drugs for S-LAM.

The application relates to the technical field of medical image processing, in particular to a lymphatic vessel segmentation method based on dynamic integrated structure perception 3D-Net, which comprises two parts of a training stage and a use stage. The training stage comprises construction, training and optimization of multiple 3D-UNet models, wherein each 3D-UNet model adopts different initialization and hyperparameter settings, so that the models have diversity and difference. The use stage comprises integrating the prediction results of the multiple 3D-UNet models, and improving the segmentation accuracy and robustness through a dynamic weight integration strategy. Finally, post-processing technology is adopted to optimize the integrated results, so that the accuracy and stability of the segmentation results are ensured. Through dynamic integration of multiple 3D-UNet models, the method combines a structure perception module and a multi-scale feature fusion strategy, significantly improves the accuracy and robustness of lymphatic vessel segmentation, and provides more reliable image data support for clinical diagnosis and treatment.

The disclosure relates in part to the discovery that slow-flow vascular malformations (which can be venous and / or lymphatic) can be treated using direct intralesional delivery of an active drug, such as but not limited to a mTOR inhibitor, such as but not limited to temsirolimus, or a salt or solvate thereof.

The application discloses a use of an active ingredient in repairing heart tissue damage. Specifically, the application discloses an active ingredient which can be used for repairing heart tissue damage and treating diseases related to lymphatic vessel abnormalities, and the active ingredient comprises a TBX1 protein, a coding sequence of the TBX1 protein, or a promoter of the TBX1 protein, or a combination thereof. The TBX1 protein can promote the proliferation of heart lymphatic vessel endothelial cells, play an immune regulation role, promote the establishment of an immune inhibition microenvironment in myocardium after heart tissue damage, inhibit an autoimmune reaction after the heart tissue damage, relieve concurrent heart tissue inflammation, and promote the repair and regeneration of the damaged heart tissue.

Preferred embodiments relate to devices for performing a lymphovenous bypass procedure. A first ring is secured to tissue connected to at least one lymphatic channel of a patient and a second ring is attached to a vein of the patient. An end of the lymphatic channel that extends through the first ring is inserted into an open end of the vein and the rings are connected together to establish fluid flow from the lymphatic channel into the vein.

This invention belongs to the field of pharmaceutical technology and relates to the research and application of drugs for the treatment of lymphedema, specifically the application of systemic artemisinin in the treatment of secondary lymphedema. Specifically, this invention provides the use of artemisinin or its derivatives in the preparation of drugs or formulations for the prevention and / or treatment of lymphedema, wherein the drugs or formulations are used to: relieve lymphedema, relieve fat deposition caused by lymphedema, and / or promote lymphatic vessel regeneration.

1. Name of the product in this design: Meridian Brush. 2. Purpose of this design: To unclog the lymphatic vessels and meridians of the face. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.

The disclosure relates to devices and methods for the treatment of edema that uses an impeller with a balloon that may be mounted on the impeller housing. The invention provides devices and methods for treatment of edema that use an indwelling catheter with an impeller to lower pressure at an outlet of a lymphatic duct and a balloon on the impeller to guide and to restrict blood flow. The balloon restricts return flow from the jugular and guides that flow into the impeller cage. By funneling the flow into the impeller cage, a rate of flow down the vessel may be increased, resulting in a lateral pressure decrease effecting the lymphatic outlet. Because the lymphatic outlet is subject to a pressure decrease, fluids in the lymphatic system drain to the outlet and into the circulatory system.